Clinical trials: Osteopenia
Alveolar Bone Loss, Periodontal Diseases
GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery
GUIDOR Growth Factor Enchanted Bone Graft Substitute (GFeBGS) when used in periodontal surgery will shown greater gum and bone regeneration when compare to bone graft substitute alone. Also, to find the optimal dose.
- Trial name
- NCT01728844
- Testing
- beta-tricalcium phosphate alone, GFeBGS 0.1%, GFeBGS 0.3%
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Sunstar Americas
Periodontitis, Alveolar Bone Loss
Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)
This study aims to verify the effectiveness of Trafermin (recombinant human basic fibroblast growth factor) in stimulating regeneration of periodontal tissue lost by periodontitis and to evaluate the safety of such stimulation.
- Conditions
- Periodontitis, Alveolar Bone Loss, Periodontal Attachment Loss
- Trial name
- NCT00734708
- Testing
- Trafermin (genetical recombination)
- Where
- 21 sites in Japan
- Volunteers
- 328 people
- Sponsor
- Kaken Pharmaceutical
Osteoporosis
Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis
The purpose of this study is to determine whether BA058 is effective in building bone in postmenopausal women with osteoporosis.
- Trial name
- NCT00542425
- Testing
- teriparatide, BA058 20 µg, BA058 40 µg
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Radius Health, Inc.
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Osteopenia, Osteoporosis
Food Trial Evaluating Fecal Abundance of SBD111 With Once-Daily Versus Twice-Daily Administration in Healthy Adults
The purpose of this study is to determine whether a modified formulation and daily intake schedule of SBD111 results in similar levels of probiotic microbes in the gut compared with the currently used formulation.
- Conditions
- Osteopenia, Osteoporosis, Menopause Related Conditions, Probiotic Intervention
- Trial name
- NCT07538167
- Testing
- SBD111(current formulation), SBD111 (new formulation)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Solarea Bio, Inc
Postmenopausal, Osteopenia
Effects of Denosumab on the Pharmacokinetics of Etanercept
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis…
- Conditions
- Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
- Trial name
- NCT01294397
- Testing
- Etanercept, Denosumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Amgen
Osteoporosis, Osteopenia
Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass
This study is being conducted to evaluate the effect treatment has on serum P1NP levels, a biomarker of bone formation in postmenopausal women with low bone mass.
- Trial name
- NCT01604057
- Testing
- ZT-034 Low Dose Nasal Spray, ZT-034 Mid Dose Nasal Spray, ZT-034 High Dose Nasal Spray
- Volunteers
- 130 people
- Sponsor
- Azelon Pharmaceuticals
Osteoporosis, Osteoporosis, Age-Related
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.
- Conditions
- Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis
- Trial name
- NCT03512262
- Testing
- Abaloparatide
- Where
- 34 sites in United States, Italy and 1 more
- Volunteers
- 228 people
- Sponsor
- Radius Health, Inc.
Osteopenia
Evaluation of the Spry Belt for Improving Bone Quality
The purpose of this research study is to evaluate the safety and effectiveness of the Spry Belt. The Spry Belt is intended to deliver energy to the user's skeleton to reduce the progression of age-related decrease in bone quality…
- Trial name
- NCT03986203
- Testing
- Spry Belt
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Theranova, L.L.C.
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Healthy, Osteopenia
Clinical Study to Predict the Risk of Bone Fractures With the POROUS Ultrasound Device
Osteoporosis is a widespread medical condition among older people. It causes the bones to weaken and become more likely to break.
- Conditions
- Healthy, Osteopenia, Osteoporosis
- Trial name
- POROUS-preFX (NCT06567054)
- Testing
- Measurements with the POROUS R3C ultrasound device at the midshaft tibia, DXA measurement of the hip and lumbar spine, DXA-based Vertebral Fracture Assessment (VFA)
- Where
- 6 sites in Austria, Germany and 1 more
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- POROUS GmbH
Lupus
To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids
The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).
- Trial name
- NCT00053560
- Testing
- Prasterone (GL701)
- Where
- 26 sites in United States, Mexico
- Volunteers
- 155 people
- Sponsor
- Genelabs Technologies
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Osteoporosis, Osteopenia
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects…
- Trial name
- NCT00330460
- Testing
- Alendronate, Denosumab
- Volunteers
- 1,189 people
- Sponsor
- Amgen
Osteopenia, Generalized
Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women
A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of Lifenol® in Improving Bone Status in Postmenopausal Osteopenic Women.
- Trial name
- NCT04004013
- Testing
- Lifenol®
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Givaudan France Naturals
Low Bone Mineral Density, Postmenopausal Osteoporosis
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low…
- Trial name
- NCT00896532
- Testing
- Alendronate, Teriparatide, Romosozumab
- Volunteers
- 419 people
- Sponsor
- Amgen
Bone Loss
A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.
The purpose of the study was to evaluate the effect of Pamidronate on bone mineral density loss and fracture rates up to 2 years, in post renal-transplant subjects on a Ciclosporin A and glucocorticoid based immunosuppressive…
- Trial name
- SMART (NCT00738257)
- Testing
- Pamidronate
- Where
- United Kingdom
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Osteopenia
DXA Precision and Accuracy Comparison Study
This study is being conducted to examine the performance of three common DXA machines (1) Lunar iDXA, (2) Lunar Prodigy and (3) Hologic Discovery A in measuring bone density and body fat.
- Trial name
- DXA P&A (NCT01530477)
- Testing
- Lunar Prodigy (GEHC), Lunar iDXA (GEHC), Discovery A (Hologic
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Bone Loss
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
- Trial name
- LACE (NCT00674453)
- Testing
- Lasofoxifene
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- Ligand Pharmaceuticals
Post-Menopausal Osteopenia
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
This 2 arm study will compare the effect of oral Bonviva (150mg, monthly) and placebo on parameters of bone micro-architecture, assessed by CT scan, bone turnover and bone mineral density.
- Trial name
- NCT00545207
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 4 sites in France
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche